These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab. Tomsitz D; Hein R; Biedermann T; Kohlmeyer J J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283 [No Abstract] [Full Text] [Related]
28. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206 [TBL] [Abstract][Full Text] [Related]
29. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma. Lasocki A; Smith K J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645 [TBL] [Abstract][Full Text] [Related]
30. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma. Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986 [TBL] [Abstract][Full Text] [Related]
31. Dose-dependent toxicity of ipilimumab in metastatic melanoma. Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367 [No Abstract] [Full Text] [Related]
33. A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment. Fukuchi K; Shimauchi T; Fujiyama T; Ito T; Honda T Eur J Dermatol; 2023 Oct; 33(5):550-551. PubMed ID: 38297931 [No Abstract] [Full Text] [Related]
34. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675 [TBL] [Abstract][Full Text] [Related]
35. Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange. Waki Y; Nobeyama Y; Chujo S; Asahina A J Dermatol; 2024 May; 51(5):e149-e150. PubMed ID: 38010735 [No Abstract] [Full Text] [Related]
36. Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event. Mangas C; Leoni-Parvex S; Spataro V Cancer Immunol Immunother; 2020 Nov; 69(11):2409-2410. PubMed ID: 32964272 [No Abstract] [Full Text] [Related]
37. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma. Latchman J; Guastella A; Tofthagen C Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610 [TBL] [Abstract][Full Text] [Related]
38. Nivolumab plus ipilimumab in metastatic colorectal cancer. Gourd E Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861 [No Abstract] [Full Text] [Related]
40. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. Afzal MZ; Shirai K J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]